We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marsh Sees 8.2% Health Cost Surge in 2027: Consulting Growth Ahead?
Read MoreHide Full Article
Key Takeaways
MRSH expects employer health costs to rise 8.2% in 2027, topping $20,000 per worker after a 7.3% 2026 rise.
Drug costs rose 9.7% at large employers as GLP-1 coverage fell to 41% in 2026 from 49% a year earlier.
MRSH's Health and Benefits revenue rose 5% y/y underlying to $578 million in Q3 2026.
Marsh & McLennan Companies, Inc. (MRSH - Free Report) released its 2026 survey of employer health plans, showing how companies are fighting rising medical costs without abandoning employee coverage. The study found average benefit costs reached $18,777 per worker for 2026, up 7.3%. Employers expect employer-sponsored benefit costs to rise another 8.2% in 2027, pushing spending above $20,000 per employee.
Marsh highlighted changes in prescription coverage, including employers scaling back access to expensive GLP-1 weight-loss drugs or requiring coaching programs. It also pointed to growing interest in plans that steer employees toward carefully selected healthcare providers. Simon Camaj, Marsh’s US Health and Benefits leader, warned that unchecked increases could squeeze hiring and pay budgets, making smarter benefit design increasingly necessary.
The findings show healthcare is becoming a harder, more unpredictable expense for employers and workers to absorb. Prescription drug costs climbed 9.7% among large companies, while GLP-1 coverage fell from 49% of large employers in 2025 to 41% in 2026.
Employees felt the strain too: monthly family contributions in common PPO plans increased from $709 to $753, adding $528 annually. With health coverage influencing recruitment and retention, employers must carefully balance savings against the risk of frustrating staff or weakening benefits they value.
Rising benefit costs create both opportunity and urgency for Marsh. Companies facing tighter budgets may seek its guidance on plan design, pharmacy spending and provider networks, potentially supporting consulting demand. Reflecting momentum in this business, Marsh's Health and Benefits revenues grew 5% on an underlying basis in the third quarter of 2026, reaching $578 million. The business generated $1.85 billion in revenues during the first nine months, with growth across all regions.
How Are Marsh’s Peers Placed?
Peers like Aon plc (AON - Free Report) and Willis Towers Watson Public Limited Company (WTW - Free Report) are also positioned to benefit as employers seek relief from escalating healthcare expenses.
Aon's Health Solutions revenues climbed 6% year over year to $992 million in third-quarter 2026, supported by new business and strong client retention. Meanwhile, WTW's Health business delivered 6% organic revenue growth, benefiting from new business and renewals across regions. WTW also cited sustained employer demand for assistance in designing and managing healthcare programs amid elevated costs. While these trends indicate a favorable consulting environment, growing competition could limit pricing power and impact gains.
MRSH’s Price Performance, Valuation and Estimates
Shares of Marsh have gained 11.1% year to date against the industry’s decline of 6.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, Marsh trades at a forward price-to-earnings ratio of 18.21X, higher than the industry average but below its five-year median. MRSH currently has a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Marsh’s 2026 earnings implies a 7.6% increase year over year.
Image: Shutterstock
Marsh Sees 8.2% Health Cost Surge in 2027: Consulting Growth Ahead?
Key Takeaways
Marsh & McLennan Companies, Inc. (MRSH - Free Report) released its 2026 survey of employer health plans, showing how companies are fighting rising medical costs without abandoning employee coverage. The study found average benefit costs reached $18,777 per worker for 2026, up 7.3%. Employers expect employer-sponsored benefit costs to rise another 8.2% in 2027, pushing spending above $20,000 per employee.
Marsh highlighted changes in prescription coverage, including employers scaling back access to expensive GLP-1 weight-loss drugs or requiring coaching programs. It also pointed to growing interest in plans that steer employees toward carefully selected healthcare providers. Simon Camaj, Marsh’s US Health and Benefits leader, warned that unchecked increases could squeeze hiring and pay budgets, making smarter benefit design increasingly necessary.
The findings show healthcare is becoming a harder, more unpredictable expense for employers and workers to absorb. Prescription drug costs climbed 9.7% among large companies, while GLP-1 coverage fell from 49% of large employers in 2025 to 41% in 2026.
Employees felt the strain too: monthly family contributions in common PPO plans increased from $709 to $753, adding $528 annually. With health coverage influencing recruitment and retention, employers must carefully balance savings against the risk of frustrating staff or weakening benefits they value.
Rising benefit costs create both opportunity and urgency for Marsh. Companies facing tighter budgets may seek its guidance on plan design, pharmacy spending and provider networks, potentially supporting consulting demand. Reflecting momentum in this business, Marsh's Health and Benefits revenues grew 5% on an underlying basis in the third quarter of 2026, reaching $578 million. The business generated $1.85 billion in revenues during the first nine months, with growth across all regions.
How Are Marsh’s Peers Placed?
Peers like Aon plc (AON - Free Report) and Willis Towers Watson Public Limited Company (WTW - Free Report) are also positioned to benefit as employers seek relief from escalating healthcare expenses.
Aon's Health Solutions revenues climbed 6% year over year to $992 million in third-quarter 2026, supported by new business and strong client retention. Meanwhile, WTW's Health business delivered 6% organic revenue growth, benefiting from new business and renewals across regions. WTW also cited sustained employer demand for assistance in designing and managing healthcare programs amid elevated costs. While these trends indicate a favorable consulting environment, growing competition could limit pricing power and impact gains.
MRSH’s Price Performance, Valuation and Estimates
Shares of Marsh have gained 11.1% year to date against the industry’s decline of 6.4%.
From a valuation standpoint, Marsh trades at a forward price-to-earnings ratio of 18.21X, higher than the industry average but below its five-year median. MRSH currently has a Value Score of C.
The Zacks Consensus Estimate for Marsh’s 2026 earnings implies a 7.6% increase year over year.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.